Massiver Turnaround bevorstehend?
| eröffnet am: | 27.08.15 18:08 von: | biotech1x1 |
| neuester Beitrag: | 24.04.21 23:27 von: | Manuelaheqva |
| Anzahl Beiträge: | 812 | |
| Leser gesamt: | 149042 | |
| davon Heute: | 18 | |
bewertet mit 4 Sternen |
||
|
|
||
08.10.15 16:55
#151
batscherderfliesen.
da wird ganz schön unter 0,10$ abgeladen,
aber das geht auch mal zu ende.
15.10.15 15:16
#152
wuifgeja
News
Great Basin Reports 143 Revenue-Generating Customers to End Third Quarter
Great Basin Scientific, Inc.
Today : Thursday 15 October 2015
Great Basin Scientific, Inc. Charts.
24 percent customer growth in the period, sales funnel increases by 28.5 percent
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it added 28 new customers in the third quarter of 2015. As of September 30th, the company had secured 143 U.S. customers and had 64 evaluations either in-progress or scheduled, compared to 115 customers and 46 evaluations reported for the second quarter ending June 30, 2015, representing an increase of 24 percent and 39 percent respectively. Great Basin’s sales funnel, which represents the number of customers along with active and scheduled customer evaluations, grew to 207 at the end of the third quarter, up from 161 at the end of the second quarter, an increase of 28.5 percent.
Adoption for Great Basin’s Group B Streptococcus (GBS) test—which was commercially launched on June 1, 2015—continued to expand. The Company ended the third quarter with 66 customers and potential customers either evaluating or scheduled to evaluate GBS, a 38.6 percent increase over the customer and potential customer sites for GBS reported at the end of second quarter.
“September was the strongest month for customer acquisition in the history of Great Basin—with 24 new customers added in that month alone—showing what we believe is sustained strength in our sales funnel, and continuing demand for our Group B Strep test,” said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific. “I’m extremely pleased with the strides we have made toward a shortened sales cycle and for achieving a 91 percent evaluation win-rate in the quarter, which adds to our confidence of achieving our customer acquisition guidance by the end of the year.”
Great Basin Scientific, Inc.
Today : Thursday 15 October 2015
Great Basin Scientific, Inc. Charts.
24 percent customer growth in the period, sales funnel increases by 28.5 percent
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it added 28 new customers in the third quarter of 2015. As of September 30th, the company had secured 143 U.S. customers and had 64 evaluations either in-progress or scheduled, compared to 115 customers and 46 evaluations reported for the second quarter ending June 30, 2015, representing an increase of 24 percent and 39 percent respectively. Great Basin’s sales funnel, which represents the number of customers along with active and scheduled customer evaluations, grew to 207 at the end of the third quarter, up from 161 at the end of the second quarter, an increase of 28.5 percent.
Adoption for Great Basin’s Group B Streptococcus (GBS) test—which was commercially launched on June 1, 2015—continued to expand. The Company ended the third quarter with 66 customers and potential customers either evaluating or scheduled to evaluate GBS, a 38.6 percent increase over the customer and potential customer sites for GBS reported at the end of second quarter.
“September was the strongest month for customer acquisition in the history of Great Basin—with 24 new customers added in that month alone—showing what we believe is sustained strength in our sales funnel, and continuing demand for our Group B Strep test,” said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific. “I’m extremely pleased with the strides we have made toward a shortened sales cycle and for achieving a 91 percent evaluation win-rate in the quarter, which adds to our confidence of achieving our customer acquisition guidance by the end of the year.”
16.10.15 13:17
#156
Moneyplus
Mich würde mal interessieren
wieviele Shares wir jetzt genau haben.
Wenn es bei dieser Deckelung von 200 Mio. geblieben sein sollte, hätten wir derzeit eine MK von rd. 20 Mio. USD.
Eigentlich ein Witz.
Wenn es bei dieser Deckelung von 200 Mio. geblieben sein sollte, hätten wir derzeit eine MK von rd. 20 Mio. USD.
Eigentlich ein Witz.
16.10.15 13:49
#157
wuifgeja
es dürften
sogar etwas weniger sein, glaube irgendwas um die 190.630.000 Stück was ein MK von 17,92mio $ bedeutet!
http://finance.yahoo.com/q/ks?s=GBSN+Key+Statistics
bin mir aber nicht sicher wie aktuell die Zahlen sind! aber es durften 90 Tage keine mehr "gedruckt" werden und der Zeitraum geht glaube ich bis ziemlich ende dieses Jahres!?!
http://finance.yahoo.com/q/ks?s=GBSN+Key+Statistics
bin mir aber nicht sicher wie aktuell die Zahlen sind! aber es durften 90 Tage keine mehr "gedruckt" werden und der Zeitraum geht glaube ich bis ziemlich ende dieses Jahres!?!
16.10.15 13:57
#158
wuifgeja
Korrektur
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Shares of Common Stock that may be acquired by an individual or group within 60 days of September 21, 2015, pursuant to the exercise of options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Percentage of ownership is based on 190,630,641 shares of Common Stock outstanding prior to September 21, 2015.
Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of Common Stock shown to be beneficially owned by them, based on information provided to us by such stockholders. Unless otherwise indicated, the address for each director and executive officer listed is: c/o Great Basin Scientific, Inc., 2441 South 3850 West, Salt Lake City, UT 84120.
All Executive Officers and Directors as a Group (7 Persons)
9,332,489
Hattest Recht, sind genau 200mio!
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Shares of Common Stock that may be acquired by an individual or group within 60 days of September 21, 2015, pursuant to the exercise of options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Percentage of ownership is based on 190,630,641 shares of Common Stock outstanding prior to September 21, 2015.
Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of Common Stock shown to be beneficially owned by them, based on information provided to us by such stockholders. Unless otherwise indicated, the address for each director and executive officer listed is: c/o Great Basin Scientific, Inc., 2441 South 3850 West, Salt Lake City, UT 84120.
All Executive Officers and Directors as a Group (7 Persons)
9,332,489
Hattest Recht, sind genau 200mio!
16.10.15 16:01
#159
Fortuna89
Kurssturz
Kann mich einer aufklären wieso der Kurs so dermaßen runtergedrückt worden ist ?
LG
PS: Bin relativ neu hier :)
LG
PS: Bin relativ neu hier :)
21.10.15 21:18
#162
Jackson Coalman.
@Frank72 - Es war doch wohl klar
das die Aktie heute erst einmal "abschmieren" wird. Es wusste doch jeder informierte Kaeufer wie die NASDAQ funktioniert. http://stocknewsflow.com/...8_000091228215000391_0000912282-15-000391
17.11.15 11:05
#164
Obelax
Quartalzahlen
Schauen mal richtig gut aus bin mal gespannt auf die eröffnung gestern nochmal nachgelegt... Sind ja 2 FDA zulassungen am laufen?
On September 1, 2015 submitted 510(k) application to the FDA for Staph ID/R Blood Culture, its first multiplex panel, capable of detecting Staph aureus, Staphylococcus lugdunensis and Staphylococcus epidermidis as well as the presence of the mecA gene, a drug resistance marker that enables resistance to methicillin and creates the superbug MRSA
·
On October 8, 2015 submitted 510(k) application to the FDA for its fourth test, Shiga Toxin Direct. Upon Shiga Toxin Direct FDA approval, Great Basin will have the only stand-alone molecular test for detecting Shiga toxin-producing E. coli (STEC) and the serotype O157 directly from patient specimen
On September 1, 2015 submitted 510(k) application to the FDA for Staph ID/R Blood Culture, its first multiplex panel, capable of detecting Staph aureus, Staphylococcus lugdunensis and Staphylococcus epidermidis as well as the presence of the mecA gene, a drug resistance marker that enables resistance to methicillin and creates the superbug MRSA
·
On October 8, 2015 submitted 510(k) application to the FDA for its fourth test, Shiga Toxin Direct. Upon Shiga Toxin Direct FDA approval, Great Basin will have the only stand-alone molecular test for detecting Shiga toxin-producing E. coli (STEC) and the serotype O157 directly from patient specimen
17.11.15 11:47
#165
Karlmann
Zuversicht, es ist kein Penny Stock hier!!
Hallo & Gruss
Bin bei AEterna Zentaris raus, und habe den Rest von AZ bei Great Basin Investiert.
Ich denke es läuft hier besser ab.
Bin bei AEterna Zentaris raus, und habe den Rest von AZ bei Great Basin Investiert.
Ich denke es läuft hier besser ab.
17.11.15 11:53
#166
Moneyplus
Wieso ist das
kein Penny Stock ?
Die drucken auch Shares wie blöde (im Moment gedeckelt bei 200 Mio., aber das heißt ja nicht das nicht weitere folgen).
Zahlen fand ich jetzt auch nicht berauschend (immer noch großer Quartalsverlust).
Also gewisse Paralelen mit AEZS tun sich da bei mir schon auf (und die haben keinen potentiellen Blockbuster wie AEZS)
Die drucken auch Shares wie blöde (im Moment gedeckelt bei 200 Mio., aber das heißt ja nicht das nicht weitere folgen).
Zahlen fand ich jetzt auch nicht berauschend (immer noch großer Quartalsverlust).
Also gewisse Paralelen mit AEZS tun sich da bei mir schon auf (und die haben keinen potentiellen Blockbuster wie AEZS)
18.11.15 04:48
#169
Jackson Coalman.
Ein Schlag
auf die Rippen durch http://www.investmentlosslawyers.com/...id=CPa4zbKimMkCFc5efgodkEsEPQ
18.11.15 06:24
#170
Obelax
Die anwälte
Sind wie die ratten... Ist gestern zum schluss noch ziemlich abgeschmiert
18.11.15 09:13
#171
Karlmann
an Jackson Coal
Ist nur Werbung!
Für die wäre VW Aktionär eine gute Adresse.
Für die wäre VW Aktionär eine gute Adresse.
18.11.15 11:44
#172
biotech1x1
Bin raus aber beobachte weiter
Ein echtes Trauerspiel mit GBSN. Mittlerweile sehe ich wirklich immer wieder dunkle Schatten auf den Unternehmen, die in irgendeiner Form mit Dawson James kooperieren oder kooperiert haben. Dabei hat GBSN Produkte und Technologien, um in höheren Ligen zu spielen. Und Roth als Partner könnte weiter einiges richten. Für diejenigen, die hier noch investiert sind viel Glück. Ich hoffe das Blatt ändert sich zu euren Gunsten.
LG, biotech
LG, biotech
18.11.15 20:23
#173
kuras15
Untersuchung ein im Auftrag von
von Great Basin Scientific, Inc. Aktionäre - GBSN
http://www.businesswire.com/news/home/...asin-Scientific-Shareholders
http://www.businesswire.com/news/home/...asin-Scientific-Shareholders
24.11.15 21:38
#174
kuras15
biotech
Ich hoffe für dich, dass du wieder drin bist, wäre schade wenn nicht.